Target: Chk1 | Disease State: Solid Tumors

Introduction / Brief Description

Prexasertib is a small-molecule Chk1 inhibitors invented by Array and being developed by Eli Lilly and Company. Lilly is responsible for all clinical development and commercialization activities. Prexasertib is advancing in Phase 2 clinical trials for cancer.

Chk1 is a protein kinase that regulates the tumor cell's response to DNA damage often caused by treatment with chemotherapy. In response to DNA damage, Chk1 blocks cell cycle progression in order to allow for repair of damaged DNA, thereby limiting the efficacy of chemotherapeutic agents. Inhibiting Chk1 in combination with chemotherapy can enhance tumor cell death by preventing these cells from recovering from DNA damage.

Clinical Trials

To learn more about prexasertib clinical trials, click here.

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of our clinical trials.